Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the newly hired Commercial Director for the Western U.S. The option, covering 17,000 shares of common stock at an exercise price of $3.20 per share, was granted on May 5, 2026, as a material inducement for Keefe to join the company.
The grant, made under Nasdaq Listing Rule 5635(c)(4), vests over four years: one-fourth on the one-year anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the next three years, contingent on Keefe's continued service. The option carries a 10-year term and is subject to a standard inducement stock option agreement.
This expansion of the commercial team reflects increasing demand for Aclarion's Nociscan platform, which leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to help physicians identify the location of chronic low back pain. According to the company, Nociscan has seen triple-digit growth in utilization, underscoring the need for additional commercial leadership in key regions like the Western U.S.
Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. By receiving MRS data from an MRI machine via cloud connection, the platform extracts and quantifies chemical biomarkers associated with disc pain, then uses proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights to optimize treatment strategies.
Aclarion's focus on chronic low back pain addresses a significant market need, as back pain is a leading cause of disability worldwide. The company's technology aims to improve treatment success rates by pinpointing the exact location of pain, potentially reducing unnecessary surgeries and improving patient outcomes.
For more information about Aclarion and Nociscan, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
